Drug-, dose- and sex-dependent effects of chronic fluoxetine, reboxetine and venlafaxine on open-field behavior and spatial memory in rats (2015)
© 2014 Elsevier B.V. In an effort to address the need to include both sexes in studies of effects of the SSRI fluoxetine, the NRI reboxetine and the SNRI venlafaxine on anxiety-related behavior and memory along with the use of chronic drug administration, male and female PVG/c rats were fed diets containing two doses of each drug for 21 days. The rats' anxiety level was then assessed in an open field. Short-term spatial memory for a brightness change in a Y maze was also measured. While there was little evidence of anxiolytic effects of any of the drugs, both fluoxetine and, to a l esser extent, venlafaxine appeared to be mainly anxiogenic in their action depending on both dose and sex. Reboxetine was relatively ineffective in this respect. Ability to locate the Y-maze arm that had changed (from white to black) seemed to be impaired for male (but not female) rats by both fluoxetine and venlafaxine and, to a much lesser extent, by reboxetine. Given the relative ineffectiveness of reboxetine in either test, it is possible that the effects of the other two drugs on both anxiety and memory were mainly due to their serotonin reuptake inhibiting properties. The differences that occurred between males and females in responsiveness to all three drugs supported the long-held view that both sexes should be investigated in studies of this sort, especially in view of reports of sex differences in effects of clinically prescribed antidepressants.
CitationGray VC, Hughes RN (2015). Drug-, dose- and sex-dependent effects of chronic fluoxetine, reboxetine and venlafaxine on open-field behavior and spatial memory in rats. Behavioural Brain Research. Volume 281, 15 March 2015, Pages 43-54
This citation is automatically generated and may be unreliable. Use as a guide only.
KeywordsScience & Technology; Life Sciences & Biomedicine; Behavioral Sciences; Neurosciences; Neurosciences & Neurology; Fluoxetine; Reboxetine; Venlafaxine; Rats; Anxiety; Spatial memory; FORCED SWIMMING TEST; REUPTAKE INHIBITOR REBOXETINE; ANXIETY-RELATED BEHAVIOR; ELEVATED PLUS-MAZE; MAJOR DEPRESSION; DOUBLE-BLIND; ANTIDEPRESSANT DRUGS; HEALTHY-VOLUNTEERS; GENDER-DIFFERENCES; HOODED RATS
ANZSRC Fields of Research32 - Biomedical and clinical sciences::3214 - Pharmacology and pharmaceutical sciences::321402 - Clinical pharmacology and therapeutics
31 - Biological sciences::3109 - Zoology::310906 - Animal neurobiology
17 - Psychology and Cognitive Sciences::1701 - Psychology::170101 - Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology)
11 - Medical and Health Sciences::1109 - Neurosciences
RightsCreative Commons Attribution Non-Commercial No Derivatives License
Showing items related by title, author, creator and subject.
Supplementation of blackcurrant anthocyanins increased cyclic glycine-proline in the cerebrospinal fluid of Parkinson patients: Potential treatment to improve insulin-like growth factor-1 function Fan D; Alamri Y; Liu K; Harris P; Brimble M; Dalrymple-Alford J; Prickett T; Menzies O; Laurenson A; Anderson T; Guan J; MacAskill M (2018)© 2018 by the authors. Licensee MDPI, Basel, Switzerland. Background: Insulin-like growth factor-1 (IGF-1) function is impaired in Parkinson disease. Cyclic glycine-proline (cGP), a metabolite of IGF-1, is neuroprotective ...
Single-patient multiple crossover studies to determine the effectiveness of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids: a pilot study Nikles, J.; Mitchell, G.K.; Hardy, J.; Senior, H.; Carmont, S.A.; Schluter, P.J.; Vora, R.; Currow, D.; Yelland, M. (University of Canterbury. School of Health Sciences, 2016)Paracetamol is a useful adjunct when used in combination with “weak opioids” for chronic pain in palliative care patients with advanced cancer, however it is not certain that there is continuing benefit when used in ...
Testing the effectiveness of pilocarpine drops for dry mouth in advanced cancer using aggregated n-of-1 trials: a pilot study Nikles, J.; Mitchell, G.K.; Hardy, J.; Agar, M.; Senior, H.; Carmont, S.A.; Schluter, P.J.; Good, P.; Vora, R.; Currow, D. (University of Canterbury. School of Health Sciences, 2015)Purpose : Dry mouth is a common and troublesome symptom in palliative care. Pilocarpine is a cholinergic agent that promotes salivation. We aimed to test the effectiveness of pilocarpine drops compared to placebo, for ...